- Home
- NXTC vs IMNN Comparison
NXTC vs IMNN Comparison
Compare NXTC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- IMNN
- Stock Information
- Founded
- NXTC 2015
- IMNN 1982
- Country
- NXTC United States
- IMNN United States
- Employees
- NXTC N/A
- IMNN N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- IMNN Health Care
- Exchange
- NXTC Nasdaq
- IMNN Nasdaq
- Market Cap
- NXTC 13.9M
- IMNN 12.1M
- IPO Year
- NXTC 2019
- IMNN 1985
- Fundamental
- Price
- NXTC $6.17
- IMNN $7.00
- Analyst Decision
- NXTC Strong Buy
- IMNN Buy
- Analyst Count
- NXTC 3
- IMNN 2
- Target Price
- NXTC $33.00
- IMNN $14.00
- AVG Volume (30 Days)
- NXTC 299.6K
- IMNN 4.1M
- Earning Date
- NXTC 08-04-2025
- IMNN 08-13-2025
- Dividend Yield
- NXTC N/A
- IMNN N/A
- EPS Growth
- NXTC N/A
- IMNN N/A
- EPS
- NXTC N/A
- IMNN N/A
- Revenue
- NXTC N/A
- IMNN N/A
- Revenue This Year
- NXTC N/A
- IMNN N/A
- Revenue Next Year
- NXTC N/A
- IMNN N/A
- P/E Ratio
- NXTC N/A
- IMNN N/A
- Revenue Growth
- NXTC N/A
- IMNN N/A
- 52 Week Low
- NXTC $2.69
- IMNN $0.37
- 52 Week High
- NXTC $20.76
- IMNN $7.66
- Technical
- Relative Strength Index (RSI)
- NXTC 62.21
- IMNN 35.49
- Support Level
- NXTC $4.75
- IMNN $7.46
- Resistance Level
- NXTC $5.23
- IMNN $9.35
- Average True Range (ATR)
- NXTC 0.56
- IMNN 1.23
- MACD
- NXTC 0.10
- IMNN 0.08
- Stochastic Oscillator
- NXTC 86.74
- IMNN 9.00
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).